You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Baricitinib
Baricitinib is a highly potent JAK1 and JAK2 inhibitor (IC50 values are 5.9 and 5.7 nM, respectively). Also inhibits Tyk2 (IC50 = 53 nM). Displays >100-fold selectivity for JAK1/2 over JAK3 (IC50 = 53 nM for JAK3). Binds AAK1, BIKE, GAK and MPSK1 in vitro (Kd values are 17.2, 39.8, 134.4 and 68.5 nM, respectively). Inhibits IL-6-induced STAT phosphorylation and subsequent pro-inflammatory chemokine (MPC-1) and cytokine (IL-17 and IL-22) production in PBMCs and T-cells. Displays anti-inflammatory and disease modifying effects in the rat adjuvant arthritis model. In silico modelling predicts inhibition of SARS-CoV-2 cell entry.
Compound Libraries for Baricitinib
Baricitinib is also offered as part of the Tocriscreen Kinase Inhibitor Library, Tocriscreen Antiviral Library and Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.
Technical Data for Baricitinib
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Baricitinib
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Baricitinib
The following data is based on the product molecular weight 371.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.69 mL||13.46 mL||26.92 mL|
|5 mM||0.54 mL||2.69 mL||5.38 mL|
|10 mM||0.27 mL||1.35 mL||2.69 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References for Baricitinib
References are publications that support the biological activity of the product.
Fridman et al (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J.Immunol. 184 5298 PMID: 20363976
Sorrell et al (2016) Family-wide structural analysis of human numb-associated protein kinases. Structure. 24 401 PMID: 26853940
Richardson et al (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 395 e30 PMID: 32032529
If you know of a relevant reference for Baricitinib, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Baricitinib, Baricitinib supplier, INCB028050, INCB, 028050, highly, potent, JAK1, JAK2, JAK3, inhibitors, inhibits, janus, kinase, Tky2, anti, inflammatory, arthritis, 28050, JAK, COVID-19, Coronavirus, 7222, Tocris Bioscience
Citations for Baricitinib
Citations are publications that use Tocris products.
Currently there are no citations for Baricitinib. Do you know of a great paper that uses Baricitinib from Tocris? Please let us know.
Reviews for Baricitinib
There are currently no reviews for this product. Be the first to review Baricitinib and earn rewards!
Have you used Baricitinib?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.